Oracle Recognized as a Leader in 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services

Oracle has been recognized as a leader in the 2025 IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services 2025 Vendor Assessment¹. The report notes that, "Oracle is bringing together its Safety One Platform, Oracle Real-World Data (ORWD), Health Data Intelligence (HDI) platform, and Oracle Cloud Infrastructure (OCI) Artificial Intelligence (AI) Services to drive its precision PV strategy."

"By bringing together its solutions for safety, data, and intelligence, Oracle is building a connected ecosystem for precision PV," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC. "This approach, combined with their regulatory expertise and extensive customer base, positions Oracle to guide the industry towards more proactive and intelligent drug safety management."

"This recognition from the IDC MarketScape further validates Oracle's pivotal role in advancing drug safety innovation and the significant investments we have made in R&D to help our customers more swiftly and safely get life-saving treatments to market," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We further believe Oracle's Safety One platform, combined with our deep domain and AI expertise, is equipping organizations to confidently navigate the complexities of modern pharmacovigilance, helping to ensure they are future-ready for evolving regulatory landscapes and safety challenges."

The report noted, "Oracle has been providing PV technology solutions and consulting services for close to three decades. It estimates that its PV revenue will grow by 20% annually in the next three years and reports that it owns close to 60% of the PV software market share. It has supported over 100,000 clinical trials, 90% of which included a PV focus. It has over 400 direct PV customers and has acquired close to 100 new customers in the past 12 months. Over 70% of all drug Individual Case Safety Reports (ICSRs) and more than 90% of all vaccine ICSRs reported to the FDA since 2017 originate in Argus."

By continuously delivering advanced, AI-powered solutions and comprehensive services, Oracle empowers its customers to optimize pharmacovigilance operations and uphold the highest standards of patient safety.

To access the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services excerpt visit: https://www.oracle.com/life-sciences/safety-solutions/

1 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services (doc # US53669225, July 2025) - https://www.oracle.com/life-sciences/safety-solutions/